Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Florian Maria WurmFlorian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Michel BierlaireBorn in 1967, Michel Bierlaire holds a PhD in Mathematical Sciences from the Facultés Universitaires Notre-Dame de la Paix, Namur, Belgium (University of Namur). Between 1995 and 1998, he was research associate and project manager at the Intelligent Transportation Systems Program of the Massachusetts Institute of Technology (Cambridge, Ma, USA). Between 1998 and 2006, he was a junior faculty in the Operations Research group ROSO within the Institute of Mathematics at EPFL. In 2006, he was appointed associate professor in the School of Architecture, Civil and Environmental Engineering at EPFL, where he became the director of the Transport and Mobility laboratory. Since 2009, he is the director of TraCE, the Transportation Center. From 2009 to 2017, he was the director of Doctoral Program in Civil and Environmental Engineering at EPFL. In 2012, he was appointed full professor at EPFL. Since September 2017, he is the head of the Civil Engineering Institute at EPFL. His main expertise is in the design, development and applications of models and algorithms for the design, analysis and management of transportation systems. Namely, he has been active in demand modeling (discrete choice models, estimation of origin-destination matrices), operations research (scheduling, assignment, etc.) and Dynamic Traffic Management Systems. As of August 2021, he has published 136 papers in international journals, 4 books, 41 book chapters, 193 articles in conference proceedings, 182 technical reports, and has given 195 scientific seminars. His Google Scholar h-index is 68. He is the founder, organizer and lecturer of the EPFL Advanced Continuing Education Course "Discrete Choice Analysis: Predicting Demand and Market Shares". He is the founder of hEART: the European Association for Research in Transportation. He was the founding Editor-in-Chief of the EURO Journal on Transportation and Logistics, from 2011 to 2019. He is an Associate Editor of Operations Research. He is the editor of two special issues for the journal Transportation Research Part C. He has been member of the Editorial Advisory Board (EAB) of Transportation Research Part B since 1995, of Transportation Research Part C since January 1, 2006.
